Abstract
Introduction
In breast cancer, the clinical and biological variables commonly used to predict the outcome of primary chirurgical treatments include regional lymph node invasion, histological grade, and hormone receptor expression. All of these parameters are well-recognized prognostic and predictive factors. Additionally, the expression of new markers associated with proliferation (Ki-67) and cell cycle (cyclin E, cyclin D1) ( ), with mitogenic and survival pathways (HER tyrosine kinase receptor family) ( ) and with invasion processes 1 2
(urokinase-type Plasminogen Activator, Cathepsin D) ( ; ), has also been linked to the survival of breast cancer patients or to their 3 4 response to hormonal or cytotoxic therapies.
Though it is now well established that some protein tyrosine kinases have a prognostic value in breast cancer, the involvement of protein tyrosine phosphatases (PTPs) is poorly substantiated for breast tumours ( ). Initially, we showed that, in a breast cancer cell line 5 model, PTP activity was involved in anti-estrogen inhibition of growth factor-stimulated proliferation ( ). Furthermore, through mutational 6
analysis of the tyrosine phosphatase gene superfamily in human cancers, a recent study identified six PTPs that are quite commonly affected ( ). Three of these enzymes, consisting of two transmembrane subtypes (PTP gamma and LAR) and one intracellular subtype 7 (PTPL1), are already known to be regulated by estrogens ( ) or their antagonists ( ) in human breast cancer cells, and they are known to 8 9 play a role in the growth of these tumours in models. in vitro PTP gamma, which has been regarded as a potential tumour suppressor gene in kidney and lung adenocarcinoma ( ), is more highly 10 expressed in normal breast tissue than in breast tumours or breast cancer cell lines ( ; We have demonstrated increased PTPL1 mRNA levels after anti-estrogen treatment ( ) and have demonstrated by using an antisense 9 strategy that PTPL1 expression and resulting regulation are crucial for mediation of 4-hydroxytamoxifen inhibitory effects on growth factor activity ( ). In addition, we have shown that PTPL1 induces apoptosis by inhibiting the PI3-kinase/Akt survival pathway through 18
IRS-1 dephosphorylation ( ). It is interesting to note that the PTPL1/PTPN13 gene presents the characteristics of a tumour suppressor 19 gene ( ; ). It is located on chromosome 4q21, a region frequently deleted in ovarian and liver cancers ( ), and its expression is 20 21 22 frequently down-regulated or silenced through promoter hypermethylation in several tumour types ( ; ). 23 24 In the present study, we compared the expression level and prognostic value of three PTPs (PTP gamma, PTPL1, and the two LAR splicing variants) in a training set of 59 breast tumours. We confirmed the expression of the LAR neuronal variant in 58 of 59 tumours, and we demonstrated that the level of PTPL1 expression is a prognostic indicator of favourable outcome for breast cancer patients. In the testing set of 291 patients that included 232 complementary tumours and had a median follow-up of 6.4 years, we confirmed that the level of PTPL1 expression is an independent prognostic marker of increased overall survival (OS) for breast cancer patients.
Patients and methods

Patients
The pilot study involved 59 breast tumour samples; the mean age of the patients was 59.7 years (range 35 81). The median follow-up -duration in living patients was 7.5 years. The number of deaths was 21, and the number of relapses was 27.
To confirm the results in a larger sample set, 232 complementary breast tumour samples were added, resulting in a testing set of 291 patients ( ). All these patients underwent surgery for locoregional disease in the Centre Oscar Lambret, the Anticancer Centre of the Table I North of France, between May 1989 and December 1991. The mean age of the patients was 57.9 years (range 26 90). 
Tumour samples
All tumours were adenocarcinomas. At the time of collection, fat and necrotic tissues were discarded, and two adjacent tumour pieces were removed. The first piece was submitted to histological studies. The second was immediately frozen in liquid nitrogen for hormone receptor (ER, PR) and RT-PCR assays. Both ER and PR levels were determined by the dextran-coated charcoal method as described Table II inserm-00340622, version 1 -21 Nov 2008 3 9 To confirm the specificity of the sequences chosen for the primers, we performed nucleotide-nucleotide BLASTn against a database of expressed sequence tags and nr (the nonredundant set of the GenBank, EMBL, and DDBJ database sequences). To avoid amplification of contaminating genomic DNA, one of the two primers consisted of sequences derived from two adjacent exons.
The relative quantification of PTP gene expression was performed using the comparative cycle threshold (C ) method where the C T T parameter is defined as the cycle number at which the fluorescent signal is first detectable. This method is based on the use of a calibrator sample and an endogenous RNA control, which permits the quantification of unknown samples. The human breast cancer cell line MCF7, which is known to express the three PTPs, was chosen as the calibrator sample (PTP expression 1), and hypoxanthine = phosphoribosyltransferase 1 (HPRT) mRNA was used as the endogenous RNA internal control. Relative PTP expression was given by the 2 , where C C patient sample C calibrator sample; with C C C .
Statistical analyses
All statistical analyses were performed using SPSS software (version 11.0). Correlations between parameters were assessed using the Spearman nonparametric test. Overall survival and relapse-free survival were analyzed using the Kaplan Meier method. Comparison between curves was carried out using the log rank test. The proportional hazard regression method of Cox ( ) was used to assess the 27 prognostic significance of parameters taken in association.
Results
Training set
The distribution of the expression levels of the three PTPs in breast cancer samples was not Gaussian ( ). PTPL1, PTP gamma 
= =
We observed that expression of the two LAR isoforms and PTP gamma did not have any prognostic value. On the other hand, the overall survival (OS) was significantly longer among patients with a high level of PTPL1 expression when compared to patients whose tumours had low levels of this protein (P 0.04 by the log-rank test).
=
Testing set
Based on the results of the training set, the PTPL1 expression level was next determined in a complementary cohort of 232 breast cancer patients. In the total cohort (291 patients), classical correlations observed in breast cancer were found between ER and PR Table III OS was found to be significantly longer among patients with a high level of PTPL1 expression (P 0.01 by the log rank test) ( ).
=
Fig. 2
Cox univariate analyses revealed that, similarly to PTPL1 expression, ER and PR expression, tumour size and node invasion were prognostic factors for global survival ( ). Multivariate analyses identified PTPL1 as an independent prognostic factor for OS; PR Table IV and tumour size, but not node invasion, also preserved their prognostic value. However, in univariate and multivariate analyses, only node involvement and tumour size were prognostic factors for relapse-free survival ( ) .  Table IV inserm-00340622, version 1 -21 Nov 2008 Interestingly, for ER (n 201) but not ER patients, OS was significantly longer among patients with high levels of PTPL1 expression + = − (P 0.034 by the log rank test for ER , P 0.3 for ER ) ( ). Fig. 3 
Discussion
In this study, we demonstrated that transcripts of PTP gamma, LAR and its neuronal isoform, and PTPL1 are expressed in almost all human breast cancers. These results confirm previous studies demonstrating the expression of phosphatases in breast cancer ( ; ). Using 8 16 the Spearman test, we showed that PTPL1 expression was positively correlated with that of ER and PR. These results are in agreement with our previous observations ( ). 28
PTP gamma and LAR are differently expressed in breast tumour and normal tissue ( ; ), and they have been shown to influence the 8 16 growth of breast cancer cell lines after ectopic surexpression ( ; ). The absence of correlations between their expression and classical 12 15 clinico-pathological features or survival did not support an effect of these PTPs in tumour growth or invasiveness; rather, it suggests the possible importance of these enzymes in the early steps of tumour development. However, translational and post-translational modifications in addition to mutations and differential splicing can also regulate the expression and activity of these two PTPs and may have caused the divergence between the findings of the previous in vitro study and our present results.
We have demonstrated that PTPL1 has a pro-apoptotic role in breast cancer cell lines. Indeed, studying anti-growth factor activity of the anti-estrogens, we found that PTPL1 mRNA levels were increased by non-steroidal partial antagonist (4-hydroxytamoxifen) or steroidal pure antagonist (ICI 182, 780) ( ), as well as by benzothiophenes ( ) without regulation by estrogens ( ). PTPL1 suppression 9 29 9
using an antisense strategy completely abrogated the antagonistic effect of 4-hydroxytamoxifen on growth factor activity, thus demonstrating that PTPL1 and its resulting regulation are crucial for the mediation of this inhibitory effect ( ). In addition, PTPL1 affected 9 apoptosis by inhibition of the IRS-1/PI3K survival pathway ( ); this inhibition was sufficient to induce apoptosis and necessary for 18
UV-induced cell death in MCF7, HEK 293 and HeLa cells ( ). 19
PTPL1 has also been implicated in the regulation of biological phenomena associated with the cytoskeleton such as cell motility and cellular adhesion ( ; ); these processes play a fundamental role in invasion and metastasis. Furthermore, PTPL1 has been implicated in 30 31 the regulation of cytokinesis in HeLa cells ( ), and in the control of the meiotic cell cycle ( ), clearly supporting its importance in cell 32 33 growth regulation. More recently, Zhu et al ( ) demonstrated that PTPL1 can inhibit HER2/Neu, a signalling pathway that is frequently 34 deregulated in breast cancer. Published studies using mutant mice that lack PTPN13 protein product or phosphatase activity did not report any effect on tumour susceptibility. Indeed none phenotypic consequences have been reported for PTPN13 KO mice ( ) and studies of 35 mice that lack PTPN13 phosphatase activity have focused on haematopoietic cell lineages and the peripheral nervous system ( ), which 36
were previously shown to express this phosphatase ( ; ). Thus, crossbreeding of these mice with mammary tumour model mice could 37 38 be used to evaluate the role of PTPL1 in tumour progression and susceptibility.
Considering its links with classical clinico-pathological features, we observed that PTPL1 expression was negatively correlated with node involvement and histoprognostic grade. This indicates that elevated expression of PTPL1 may be a molecular marker of a more differentiated phenotype.
It is well established that mRNA expression does not necessarily reflect protein expression. Indeed, gene expression is regulated at 
Figure 2
Overall survival curve based on relative PTPL1 expression levels (clinical cut-off, upper quartile) in the whole population of patients.
Numbers in parentheses indicate failures/total number of patients in each group. 
